Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Depression Screening Scores and Allergy and Gastrointestinal Medication Use in Adolescents

Author(s): Kari Harris, Pavithra Saikumar, Yojana Sunkoj, Trista Vancuren, Blessing Olufowote and Julian Dedeaux*

Volume 18, Issue 3, 2023

Published on: 10 October, 2022

Page: [335 - 339] Pages: 5

DOI: 10.2174/1574886317666220826170140

Price: $65

conference banner
Abstract

Introduction: Between 2005 and 2014, the 12-month prevalence of major depressive episodes among adolescents aged 12 to 17 years increased from 8.5% to 11.3%. Adolescent-onset depression is related to increased risk for depression and suicidal attempts in adulthood. It is known that depression is an adverse effect among adults taking OAM; however, the effect of OAM on adolescents is unknown.

Aim: The aim of this study was to describe the relationship between Patient Health Questionnaire 9- Modified (PHQ9-M) scores and OAM use among adolescents.

Methods: This study included data abstracted from charts of adolescents aged 12 to 21 years who completed a Kansas Be Healthy wellness appointment at the KUSM-W Peds Clinic in 2017. Odds ratios were used to calculate the relationship between oral allergy medication and gastrointestinal medication use among adolescents and PHQ9-M scores.

Results: Of the 425 adolescent charts analyzed, 22% (n=96) had positive PHQ9-M screens (a score of 10 or greater), and 13% (n=56) reported current use of allergy medication and/or GI medications. Adolescents taking oral allergy medication were 1.77 times more likely to have a positive PHQ9-M screen than those not taking oral allergy medication. Among adolescents on allergy medication, there was no difference in PHQ9- M scores based on the drug class (1st or 2nd generation antihistamine or Montelukast).

Conclusion: Healthcare providers must diligently explore OAM/GI use with adolescents during clinical encounters and discuss possible adverse effects of OAM on mood.

Keywords: Over the counter, allergy, gastrointestinal medication, teens, depression, adolescents.

« Previous Next »
[1]
Mojtabai R, Olfson M, Han B. National trends in the prevalence and treatment of depression in adolescents and young adults. Pediatrics 2016; 138(6): e20161878.
[http://dx.doi.org/10.1542/peds.2016-1878] [PMID: 27940701]
[2]
Siu AL. Screening for depression in children and adolescents: US preventive services task force recommendation statement. Pediatrics 2016; 137(3): e20154467.
[http://dx.doi.org/10.1542/peds.2015-4467] [PMID: 26908686]
[3]
Mullen S. Major depressive disorder in children and adolescents. Ment Health Clin 2018; 8(6): 275-83.
[http://dx.doi.org/10.9740/mhc.2018.11.275]
[4]
Patten SB, Williams JVA, Lavorato DH, et al. Patterns of association of chronic medical conditions and major depression. Epidemiol Psychiatr Sci 2018; 27(1): 42-50.
[http://dx.doi.org/10.1017/S204579601600072X] [PMID: 27784343]
[5]
Keethy D, Mrakotsky C, Szigethy E. Pediatric inflammatory bowel disease and depression: Treatment implications. Curr Opin Pediatr 2014; 26(5): 561-7.
[http://dx.doi.org/10.1097/MOP.0000000000000129] [PMID: 25010217]
[6]
Bishop J, Lemberg DA, Day A. Managing inflammatory bowel disease in adolescent patients. Adolesc Health Med Ther 2014; 5: 1-13.
[http://dx.doi.org/10.2147/AHMT.S37956]
[7]
Cairns KE, Yap MBH, Pilkington PD, Jorm AF. Risk and protective factors for depression that adolescents can modify: A systematic review and meta-analysis of longitudinal studies. J Affect Disord 2014; 169: 61-75.
[http://dx.doi.org/10.1016/j.jad.2014.08.006] [PMID: 25154536]
[8]
Malhotra S, Sahoo S. Antecedents of depression in children and adolescents. Ind Psychiatry J 2018; 27(1): 11-6.
[http://dx.doi.org/10.4103/ipj.ipj_29_17] [PMID: 30416286]
[9]
Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA 2018; 319(22): 2289-98.
[http://dx.doi.org/10.1001/jama.2018.6741] [PMID: 29896627]
[10]
Ozdemir PG, Karadag AS, Selvi Y, et al. Assessment of the effects of antihistamine drugs on mood, sleep quality, sleepiness, and dream anxiety. Int J Psychiatry Clin Pract 2014; 18(3): 161-8.
[http://dx.doi.org/10.3109/13651501.2014.907919] [PMID: 24673474]
[11]
Kay GG, Harris AG. Loratadine: A non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. Clin Exp Allergy 1999; 29(3): 147-50.
[http://dx.doi.org/10.1046/j.1365-2222.1999.0290s3147.x] [PMID: 10444229]
[12]
Laudisio A, Antonelli Incalzi R, Gemma A, et al. Use of proton-pump inhibitors is associated with depression: A population-based study. Int Psychogeriatr 2018; 30(1): 153-9.
[http://dx.doi.org/10.1017/S1041610217001715] [PMID: 28899441]
[13]
Huang WS, Bai YM, Hsu JW, et al. Use of proton pump inhibitors and risk of major depressive disorder: A nationwide population-based study. Psychother Psychosom 2018; 87(1): 62-4.
[http://dx.doi.org/10.1159/000485190] [PMID: 29306949]
[14]
Stocky A. Ranitidine and depression. Aust N Z J Psychiatry 1991; 25(3): 415-8.
[http://dx.doi.org/10.3109/00048679109062644] [PMID: 1958166]
[15]
Workgroup: Bright Futures Periodicity Schedule. Committee on practice and ambulatory medicine. (2017). 2017 recommendations for preventive pediatric health care. Pediatrics 2017; 139(4): e20170254.
[16]
Kroenke K, Spitzer RL. The PHQ-9: A new depression and diagnostic severity measure. Psychiatr Ann 2002; 32(9): 509-21.
[http://dx.doi.org/10.3928/0048-5713-20020901-06]
[17]
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 2001; 16(9): 606-13.
[http://dx.doi.org/10.1046/j.1525-1497.2001.016009606.x] [PMID: 11556941]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy